Good news

Recently, Salubris announced that the new anti-hypertension drug “Allisartan and Amlodipine tablets” (FoLitan^®) had obtained the drug registration certificate issued by NMPA.

Allisartan and Amlodipine tablets (FoLitan^®), a domestic original ARB/CCB compound preparation(Project code: SAL0107), is used for the treatment of essential hypertension, indicated for adult patients with poor blood pressure control treated with Allisartan Isoproxil alone or Amlodipine alone.

Allisartan and Amlodipine tablets (FoLitan^®) have classic components, high reliability, and well-proven antihypertensive efficacy. After the launch of the product, it will be targeting hypertension patients in varied segments, and form strategic synergy with Salubris’ listed class 1 innovative drug Xinlitan (Allisartan Isoproxil tablets) in multiple channels, enriching the innovative product pipeline in the field of hypertension, and enhance Salubris’ comprehensive competitiveness in the field of chronic disease.

| General information of drug registration certificate

· Generic name: Allisartan and Amlodipine tablets

· Dosage forms: tablet

· Strengths: Allisartan Isoproxil 240mg and Amlodipine besylate (as measured by amlodipine) 5mg tablets

· Registration classification: Chemical 2.3

· Drug approval number: 国药准字H20240016